Learn About Peripheral T-Cell Lymphoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Hematology Oncology
City of Hope
Duarte
Jasmine Zain is a Hematologist and a Hematologist Oncology expert in Duarte, California. Zain has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. She is also highly rated in 29 other conditions, according to our data. Her top areas of expertise are T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration.
Hematology
UVA Health System
University Of Virginia Physicians Group
Enrica Marchi is an Oncologist and a Hematologist in Charlottesville, Virginia. Marchi has been practicing medicine for over 21 years and is rated as an Elite expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. She is also highly rated in 7 other conditions, according to our data. Her top areas of expertise are Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Non-Hodgkin Lymphoma, and Sezary Syndrome. Marchi is currently accepting new patients.
Hematology Oncology
Jefferson Health
Corporate Headquarters
Pierluigi Porcu is an Oncologist and a Hematologist Oncology expert in Philadelphia, Pennsylvania. Porcu has been practicing medicine for over 36 years and is rated as an Elite expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. He is also highly rated in 30 other conditions, according to our data. His top areas of expertise are T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides, Bone Marrow Transplant, and Bone Marrow Aspiration. Porcu is currently accepting new patients.
Summary: This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.
Summary: This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in targeted way and delivers v...